1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Apr 2024
Admin
News Article

EFA Technologies Goes in Brazilian Market Post Anvisa Approval

EFA Technologies enters Brazilian market after Anvisa approval of its portable RevDx device

Overview

EFA Technologies, pioneers in portable blood labs, announces the start of its operations in Brazil, following approval last October of its leading portable blood lab device, RevDx, by Anvisa, the Brazilian health regulatory authority. The company also secured US$ 6.5 million in funding, boosting EFA’s mission to further improve healthcare worldwide.

RevDx, EFA’s flagship product, is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally. Its capabilities include identifying pathogens, analyzing biomarkers and aiding in disease diagnosis. Thereby revolutionizing the field of on-site diagnostics with its efficiency and precision.

RevDx

RevDx marks a significant breakthrough in medical diagnostics. It is portable, affordable and user-friendly, leveraging microscopy and AI to deliver instant results.
This not only reduces costs and saves time, but also improves the doctor-patient relationship.
With the capability to perform a full CBC count from just a single drop of blood, the device streamlines diagnostics and equips healthcare professionals with actionable insights.

Words from CEO: EFA Technologies

Yoel Ezra, CEO of EFA Technologies, said: ""We’re thrilled to witness the impact of RevDx's on healthcare. Our mission to make Medtech accessible to everybody, starting with a complete blood count test (CBC), is coming to fruition. We’re dedicated to further expanding our reach for the benefit of patients and caregivers worldwide. Entering the vast and promising Brazilian market is a testament to that.""

Guidance by Nobel Laureate

Backed by a distinguished medical board that includes Prof. Aaron Ciechanover, a 2004 Nobel Prize Laureate, EFA Technologies is poised to revolutionize healthcare on a global scale. Prof. Ciechanover's endorsement underscores the significance of RevDx's medical innovation.The potential of this 'little' device is enormous,"says Prof. Ciechanover. It opens doors to myriad clinical applications, simplifying complex processes and transforming patient care.

EFA Technologies has obtained CE certification and enters the Brazilian market with Anvisa certification for RevDx. Meanwhile, EFA is actively exploring new markets for further expansion.

From CMO: EFA

Amir Lubshevsky, EFA’s chief medical officer, adds: We're thrilled by the initial positive response from the Brazilian market. It's an exciting time for EFA Technologies as we enter this promising market. We're eager to solidify our presence and welcome further international interest in our innovative solutions.

Current Investors and Funds

In addition, EFA has secured another US$ 6.5 million in growth capital. The current round was led by existing investors and new partners such as E-Health Ventures, Venturing Tech, ARC impact ventures and the Israeli Innovation Authority.
This capital injection will accelerate product development, expand market reach and foster innovation in healthcare diagnostics.

RevDx Capabilities

RevDx is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally.
Its capabilities include identifying pathogens, analyzing biomarkers and aiding in disease diagnosis.
Thereby revolutionizing the field of on-site diagnostics with its efficiency and precision.

About EFA

EFA (Engineering for All) Technologies, based in Caesarea, Israel, was established in 2016 by a team with combined experience in medical sciences, optical and bioengineering, and a vision to bring access to proper diagnostic and healthcare to all.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!